Literature DB >> 5548298

5-fluorocytosine and urinary candidiasis.

R R Davies, D S Reeves.   

Abstract

Two patients with urinary candidiasis were treated with 5-fluorocytosine. Serum levels of the drug and a study of its excretion in urine are recorded together with a brief account of its activity in body fluids. Evidence of toxicity was not observed with dosages of from 2 to 5 g a day.

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5548298      PMCID： PMC1795260          DOI： 10.1136/bmj.1.5749.577

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  13 in total

1.  CLINICAL LABORATORY DIAGNOSIS OF URINARY TRACT INFECTIONS.

Authors:  H SENECA; P PEER
Journal:  J Urol       Date:  1965-07       Impact factor: 7.450

2.  Disseminated, fatal postpartum candidiasis with renal suppuration: case report.

Authors:  J B DAVIS; J D WHITAKER; L K DING; J H KIEFER
Journal:  J Urol       Date:  1956-06       Impact factor: 7.450

3.  Torulopsis glabrata septicaemia treated with 5-fluorocytosine.

Authors:  A J Webb; D C Speller; K G Buckler
Journal:  Lancet       Date:  1970-04-18       Impact factor: 79.321

4.  Human serum interactions with Candida albicans.

Authors:  R A Chilgren; R Hong; P G Quie
Journal:  J Immunol       Date:  1968-07       Impact factor: 5.422

5.  Factors affecting serum inhibited growth of Candida albicans and Cryptococcus neoformans.

Authors:  A T Hendry; A Bakerspigel
Journal:  Sabouraudia       Date:  1969-10

6.  Acute monilial pyohydronephrosis: report of a case successfully treated with amphotericin B continuous renal pelvis irrigation.

Authors:  J A Blum
Journal:  J Urol       Date:  1966-11       Impact factor: 7.450

7.  In vitro studies with 5-fluorocytosine.

Authors:  S Shadomy
Journal:  Appl Microbiol       Date:  1969-06

8.  Further in vitro studies with 5-fluorocytosine.

Authors:  S Shadomy
Journal:  Infect Immun       Date:  1970-10       Impact factor: 3.441

9.  The metabolism of 5-fluorocytosine-2-14-C and of cytosine-14-C in the rat and the disposition of 5-fluorocytosine-2-14-C in man.

Authors:  B A Koechlin; F Rubio; S Palmer; T Gabriel; R Duschinsky
Journal:  Biochem Pharmacol       Date:  1966-04       Impact factor: 5.858

10.  Fungus infections of the urinary tract.

Authors:  L B GUZE; L D HALEY
Journal:  Yale J Biol Med       Date:  1958-02
View more
  9 in total

1.  Torulopsis glabrata urinary tract infection treated with 5-fluorocytosine.

Authors:  D C Speller
Journal:  J Clin Pathol       Date:  1974-01       Impact factor: 3.411

2.  Use of 5-fluorocytosine in systemic candidiasis in infancy.

Authors:  M Isacson; Z Noah; J Faber; Y Herishano; L Gottfried
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

3.  Rapid, simple bioassay for 5-fluorocytosine in the presence of amphotericin B.

Authors:  R L Kaspar; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

5.  Urinary candidiasis--a mycological study.

Authors:  A J Rayan; K T BAI; A Unnissa
Journal:  Indian J Pediatr       Date:  1978-04       Impact factor: 1.967

6.  Pharmacological studies with 5-fluorocytosine.

Authors:  E R Block; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1972-06       Impact factor: 5.191

7.  Simple assay for 5-fluorocytosine in the presence of amphotericin B.

Authors:  C A Kauffman; J A Carleton; P T Frame
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

8.  The antimycotic activity of 5-fluorocytosine.

Authors:  R J Holt; R L Newman
Journal:  J Clin Pathol       Date:  1973-03       Impact factor: 3.411

9.  Bone marrow toxicity associated with 5-fluorocytosine therapy.

Authors:  C A Kauffman; P T Frame
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.